The publication of Phase I Clinical Trials in the American Journal of Perinatology on 8 August and the update on NNLX's website on 12 August about the "Additional Results submitted for Publication" is of huge importance. The 12 Aug update noted: "This new test from Nanologix offers a rapid and unique method for both, detection and determination sensitivities for Group B Strep; setting the stage for improvement in the administration of antibiotics to combat Group B Strep infections."
Take a moment and let this information sink in, especially the sensitivity testing. This so so monumental and a game changer (realizing that the petri dish method stayed the same since the end of the 1900th century and this will be the first now validated method to improve the old method). Huge.
I wouldn't be surprised, as word gets more around, intelligent investors looking at this groundbreaking tech will invest in the company. Once in a life-time opportunity, IMO. SB
"Compared to culture-based methods, the most significant advantage molecular tests offer is faster turnaround time-on average, two hours for molecular versus 24 or more for culture. On the other hand, molecular tests have a higher operator skill requirement and can cost significantly more, typically two to four times as much on a per-test basis."
PCR is 2 to 4 times more per test vs culture based!
Right on - in addition the MRSA study results may be more of a block buster than the GBS situation - MRSA has devastated some hospitals and is a major major problem I think that in the not to distant future, every patient admitted to a hospital will be tested(by nnlx petrie dish) for MRSA - internally hospitals will use nnlx method for in house testing for same - Can't understand why NNLX isn't dollar plus NOW - I am buying all I can